RNA virus capture of host chemokines: Understanding novel viral mechanisms of immune manipulation

RNA病毒捕获宿主趋化因子:了解免疫操纵的新病毒机制

基本信息

  • 批准号:
    10551229
  • 负责人:
  • 金额:
    $ 18.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-01-14 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

Unanticipated epidemics of disease caused by RNA viruses that are normally maintained in wildlife species, such as influenza A (ducks, shorebirds), Ebola (fruit bats), Zika (non-human primates), and SARS-related coronaviruses (insectivorous bats) have become an increasing global health threat. One important property of all RNA viruses is their ability to subvert the host immune response. Although RNA viruses have been shown to utilize many divergent mechanisms of immune manipulation, the acquisition of host genes such as chemokines – as we have recently demonstrated in a newly discovered RNA virus named Jeremy Point virus (JPTV) – is an exceedingly rare event. Our central hypothesis is that this virokine (virus-captured chemokine; ORF6) – characterized as an ELR+ CXC chemokine homologue similar to interleukin-8 (IL-8) – is fully functional and recruits immune cells to sites of infection. Remarkably, ORF6 was also duplicated during replication and is now evolving into a new gene (ORF5) with an alternate function. The primary goal of this project is to better understand how RNA viruses use gene capture to subvert the vertebrate immune system and cause disease. In Specific Aim 1, we will investigate the function of the JPTV virokine and ORF5 through reverse genetics, advanced immune cell microfluidics, and cross-linking mass spectrometry (XL-MS). We have already cloned, expressed and purified the JPTV virokine by affinity chromatography and demonstrated it has chemotactic activity. Using this purified protein, we will further assess its chemoattractant capabilities by immune cell-based microfluidics to determine if it may act either as an agonist (i.e., bind to immune cell receptors and trigger migration) and/or antagonist (i.e., bind to receptors without triggering migration and thus block the effects of other chemokine agonists) to various immune cells from different hosts, as well as perform XL-MS to identify putative binding partners of the virokine. Lastly, we have recently constructed a reverse genetics system for JPTV, which we will use to investigate the biological properties of mutant viruses with or without the host captured genes. In Specific Aim 2, we will determine the structural relationships of the JPTV virokine to vertebrate ELR+ CXC chemokines by X-ray crystallography and, if necessary, we can also use alternative structural methods such as nuclear magnetic resonance spectroscopy. Importantly, structural determination of the JPTV virokine (ORF6) will also provide the first step in our goal of direct comparison with its subsequent duplication event (ORF5), which we will also target for protein crystallization. To our knowledge, such structural comparisons between a stolen host gene and its duplicate (that has evolved into a different protein) has not been performed and thus would provide a new insight into RNA virus evolution that has never been previously observed.
通常在野生动物物种中存在的RNA病毒引起的意外疾病流行,如甲型流感(鸭,滨鸟),埃博拉病毒(果蝠),寨卡病毒(非人类灵长类动物)和SARS相关的冠状病毒(食虫蝙蝠)已成为日益严重的全球健康威胁。所有RNA病毒的一个重要特性是它们破坏宿主免疫反应的能力。尽管RNA病毒已被证明利用许多不同的免疫操纵机制,但获得趋化因子等宿主基因--正如我们最近在一种新发现的名为杰里米点病毒(JPTV)的RNA病毒中所证明的那样--是一种极其罕见的事件。我们的中心假设是,这种病毒因子(病毒捕获趋化因子; ORF 6)-特征为ELR+ CXC趋化因子同系物类似于白细胞介素-8(IL-8)-是完全功能性的,并招募免疫细胞到感染部位。值得注意的是,ORF 6在复制过程中也被复制,现在正在进化成一个具有替代功能的新基因(ORF 5)。该项目的主要目标是更好地了解RNA病毒如何利用基因捕获来破坏脊椎动物的免疫系统并导致疾病。在具体目标1中,我们将通过反向遗传学,先进的免疫细胞微流体技术和交联质谱(XL-MS)研究JPTV病毒因子和ORF 5的功能。我们已经通过亲和层析克隆、表达和纯化了JPTV病毒因子,并证明其具有趋化活性。使用这种纯化的蛋白质,我们将通过基于免疫细胞的微流体进一步评估其化学引诱能力,以确定它是否可以作为激动剂(即,结合免疫细胞受体并触发迁移)和/或拮抗剂(即,与受体结合而不触发迁移,从而阻断其他趋化因子激动剂的作用)至来自不同宿主的各种免疫细胞,以及进行XL-MS以鉴定病毒因子的推定结合配偶体。最后,我们最近构建了一个反向遗传学系统的JPTV,我们将使用它来研究突变病毒的生物学特性与或没有宿主捕获的基因。在具体目标2中,我们将通过X射线晶体学确定JPTV病毒因子与脊椎动物ELR+ CXC趋化因子的结构关系,如果需要,我们还可以使用替代结构方法,如核磁共振光谱。重要的是,JPTV病毒因子(ORF 6)的结构测定也将提供我们与其随后的复制事件(ORF 5)直接比较的目标的第一步,我们也将靶向蛋白质结晶。据我们所知,这种被盗的宿主基因和它的复制品(已经进化成不同的蛋白质)之间的结构比较还没有进行,因此将提供一个新的见解RNA病毒进化,以前从未观察到。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andrew Brownell Allison其他文献

Andrew Brownell Allison的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andrew Brownell Allison', 18)}}的其他基金

RNA virus capture of host chemokines: Understanding novel viral mechanisms of immune manipulation
RNA病毒捕获宿主趋化因子:了解免疫操纵的新病毒机制
  • 批准号:
    10452788
  • 财政年份:
    2022
  • 资助金额:
    $ 18.96万
  • 项目类别:
Host cell receptor variation and control of viral cross-species transmission
宿主细胞受体变异和病毒跨物种传播的控制
  • 批准号:
    8457321
  • 财政年份:
    2013
  • 资助金额:
    $ 18.96万
  • 项目类别:
Host cell receptor variation and control of viral cross-species transmission
宿主细胞受体变异和病毒跨物种传播的控制
  • 批准号:
    8642015
  • 财政年份:
    2013
  • 资助金额:
    $ 18.96万
  • 项目类别:

相似海外基金

Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10506915
  • 财政年份:
    2021
  • 资助金额:
    $ 18.96万
  • 项目类别:
Cellular membrane affinity chromatography kit for drug discovery
用于药物发现的细胞膜亲和层析试剂盒
  • 批准号:
    10325006
  • 财政年份:
    2021
  • 资助金额:
    $ 18.96万
  • 项目类别:
SBIR Phase I: A New Class of Immobilized Metal Affinity Chromatography Resins
SBIR 第一阶段:一类新型固定金属亲和色谱树脂
  • 批准号:
    1746198
  • 财政年份:
    2018
  • 资助金额:
    $ 18.96万
  • 项目类别:
    Standard Grant
Marine speciation of nickel using immobilized nickel affinity chromatography
使用固定镍亲和色谱法测定镍的海洋形态
  • 批准号:
    512537-2017
  • 财政年份:
    2017
  • 资助金额:
    $ 18.96万
  • 项目类别:
    University Undergraduate Student Research Awards
I-Corps: Commercialization of Immobilized Metal Affinity Chromatography Resins Based on Nanomaterials
I-Corps:基于纳米材料的固定化金属亲和层析树脂的商业化
  • 批准号:
    1404605
  • 财政年份:
    2014
  • 资助金额:
    $ 18.96万
  • 项目类别:
    Standard Grant
Antibody Purification via Affinity Chromatography that Utilizes the Unconventional Nucleotide Binding Site
利用非常规核苷酸结合位点通过亲和色谱法纯化抗体
  • 批准号:
    1263713
  • 财政年份:
    2013
  • 资助金额:
    $ 18.96万
  • 项目类别:
    Continuing Grant
Development of multivalent DNA network based affinity chromatography diagnostics for isolating circulating tumour cells
开发基于多价 DNA 网络的亲和色谱诊断法,用于分离循环肿瘤细胞
  • 批准号:
    425749-2012
  • 财政年份:
    2012
  • 资助金额:
    $ 18.96万
  • 项目类别:
    Postgraduate Scholarships - Master's
Next-Generation Affinity Chromatography with PEGylated Ligands
使用聚乙二醇化配体的新一代亲和色谱法
  • 批准号:
    1159886
  • 财政年份:
    2012
  • 资助金额:
    $ 18.96万
  • 项目类别:
    Standard Grant
Immobilized zirconium ion affinity chromatography for specific enrichment of phosphoproteins
用于磷蛋白特异性富集的固定化锆离子亲和层析
  • 批准号:
    19560760
  • 财政年份:
    2007
  • 资助金额:
    $ 18.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accelerating drug discovery using frontal affinity chromatography/mass spectrometry
使用正面亲和色谱/质谱加速药物发现
  • 批准号:
    234753-2000
  • 财政年份:
    2003
  • 资助金额:
    $ 18.96万
  • 项目类别:
    Collaborative Research and Development Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了